Data presented underscore ELC R&D's
leadership in skin longevity and its work to advance optimal skin
innovation methodologies that are inclusive of ethnic
differences
NEW
YORK, Oct. 12, 2023 /PRNewswire/ -- The
Estée Lauder Companies Inc. (ELC) (NYSE: EL) shared its latest
clinical research findings in an invited keynote address and podium
presentation at the 33rd International Federation of
Societies of Cosmetic Chemists (IFSCC) Congress, held in
Barcelona, Spain, in September.
Nadine Pernodet, PhD, Senior Vice President, Bioscience, ELC, and
Estée Lauder brand Lead Scientist, addressed innovation in the
beauty industry in a lecture entitled, "Harnessing Epigenetics:
from Anti-Aging to Age Reversal." Mei
Yu, MD, PhD, Executive Director, Clinical Translation,
Global Clinical & Consumer Science, Global R&D, ELC,
presented a translational clinical study titled, "Development and
validation of post-inflammatory hyperpigmentation (PIH) model in
multi-ethnicities using different induction methods."
As part of the keynote presentation, Dr. Pernodet
highlighted ELC's research over the past 15 years and findings on
how epigenetics—through the influence of external environment and
lifestyle—directly impacts skin aging. She also explained that,
with the right technologies, understanding the positive and
negative epigenetic signals provides the ability to reverse skin
aging. Data shared included from Dr. Pernodet's work on circadian
rhythm, microRNAs, mechanobiology, and longevity proteins,
exploring how the microenvironment and macroenvironment alter skin
cell activities. This body of research is central to the ongoing
development of approaches that enable innovations to shift from
anti-aging to age reversal.
"Fifteen years ago, we realized the impactful
role epigenetics could play in skin aging, and it is now
well-recognized in the scientific community that 75% of the aging
process is directly related to epigenetics," said Dr. Pernodet.
"I'm honored to have been selected to present a keynote lecture at
the IFSCC conference this year to share the latest in this
groundbreaking science that is transforming the beauty industry. As
the industry leader in this research, we remain committed to
finding new opportunities to understand how our environment and
lifestyles impact skin cells so we can move toward age
reversal."
A part of ELC's R&D department, the Clinical Translation
function is dedicated to generating new clinical insights and
methodologies and developing breakthrough technologies in select
areas to bridge fundamental scientific discoveries and actual
clinical benefits. The Clinical Translation team expands the
repertoire of in vivo testing protocols to measure
consumer-relevant benefits and assess the effects of skin care
formulations on those benefits. Consistent with ELC's commitment to
diversity and inclusion in its product offerings, Dr. Yu's podium
presentation emphasized the need to develop optimal protocols and
methodologies to address ethnic differences. The study showed a
reliable methodology to induce and evaluate the progression of PIH
and to help develop treatment options for the resolution and
prevention of PIH across multiple Fitzpatrick skin types. The team
followed the time courses of inflammatory response and pigmentation
for three different PIH induction methods in Caucasian, Asian, and
African American study participants to identify the optimal
induction methods to evaluate anti-hyperpigmentation
technologies.
"This work represents a significant advancement because it helps
facilitate better understanding of the dynamic development and
progression of PIH as well as post-inflammatory erythema (PIE),
their underlying mechanisms, and their manifestations across skin
phototypes and ethnicities," said Dr. Yu. "Implementing this
protocol will better enable the development of novel and fully
inclusive treatment options for its resolution."
The work presented by ELC scientists at the 33rd
IFSCC Congress reflects advances in ELC's core scientific
platforms, including epigenetics, as well as our commitment to
pursuing research that is inclusive of skin types and ethnicities
from around the globe in order to develop methods, technologies,
and products that meet the needs and desires of our diverse
consumers. Around the world, ELC is dedicated to cutting-edge
science with multidisciplinary expertise ranging from basic science
and advanced technologies to the intersections of physics,
chemistry, biology, and engineering. The company has 75 years of
formulation authority and is deeply integrated into the scientific
community, regularly presenting at leading events and publishing in
peer-reviewed journals. ELC has a commitment to advancing women in
STEM; within its own operations, all of the company's R&D and
innovation laboratories worldwide are led by women, and more than
half of its scientists, engineers, and technical professionals are
women.
About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world's
leading manufacturers, marketers, and sellers of quality skin care,
makeup, fragrance, and hair care products, and is a steward of
luxury and prestige brands globally. The company's products are
sold in approximately 150 countries and territories under brand
names including: Estée Lauder, Aramis, Clinique, Lab Series,
Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin
Paris, TOM FORD, Smashbox, AERIN
Beauty, Le Labo, Editions de Parfums
Frédéric Malle, GLAMGLOW, KILIAN
PARIS, Too Faced, Dr.Jart+, and the DECIEM family of brands,
including The Ordinary and NIOD.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/the-estee-lauder-companies-highlights-key-epigenetics--multi-ethnic-translational-clinical-research-at-33rd-ifscc-congress-301954276.html
SOURCE The Estée Lauder Companies